Treatment of hypertensive patients with coexisting coronary arterial disease

Current Opinion in Cardiology

Volumn 18, Issue 4, 2003, Pages 268-271

  Docherty, Andrew ^a   Dunn, Francis G ^a  

^a STOBHILL HOSPITAL   (United Kingdom)

Author keywords

Antihypertensive; Coronary artery disease; Guidelines; Hypertension

Indexed keywords

ANGIOTENSIN II ANTAGONIST; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN; THIAZIDE DIURETIC AGENT; VERAPAMIL;

ANGINA PECTORIS; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ANTIHYPERTENSIVE AGENTS; BENZOTHIADIAZINES; BLOOD PRESSURE; COMORBIDITY; CORONARY ARTERIOSCLEROSIS; DIURETICS; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 0041379746     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-200307000-00005     Document Type: Review

References (22)

1. Collins R, Peto R, MacMahon S, et al.: Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990, 335:827-838.
2. Muntner P, He J, Roccella EJ, et al.: The impact of JNC-VI guidelines on treatment recommendations in the US population. Hypertension 2002, 39:897-902. Despite the introduction of clear guidelines, the prevalence of untreated or inadequately treated hypertension remains high.
3. Vasan RS, Beiser A, Seshadri S, et al.: Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002, 287:1003-1010. If they live long enough, almost all middle-aged males and females will develop hypertension. This paper provides data valuable to patients and epidemiologists.
4. Franklin SS, Larson MG, Khan SA, et al.: Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation 2001, 103:1245-1249.
5. Domanski M, Mitchell G, Pfeffer M, et al.: Pulse pressure and cardiovascular disease-related mortality: Follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 2002, 287:2677-2683. Further evidence from a well-defined cohort that with increasing age, systolic blood pressure and pulse pressure play an increasing role in predicting risk.
6. Morrison AC, Bray MS, Folsom AR, et al.: ADD1 460W allele associated with cardiovascular disease in hypertensive individuals. Hypertension 2002, 39:1053-1057. Confirmation that a candidate gene does play a role in hypertension and cardiovascular morbidity. Many more similar studies are to be expected as the genetic characteristics of large cohorts are analyzed.
7. Strawn WB, Ferrario CM: Mechanisms linking angiotensin II and atherogenesis. Curr Opin Lipidol 2002, 13:505-512. Excellent review of the mechanisms by which modulation of the angiotensin II may have beneficial cardiovascular effects other than by simple blood pressure reduction.
8. Zhuo JL, Mendelsohn FA, Ohishi M: Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 2002, 39:634-638. There is increasing interest in improving the endothelial function of coronary artery bypass conduits. ACE inhibitors may do this by an effect on nitric oxide production.
9. Mogensen CE, Neldam S, Tikkanen I, et al.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000, 321:1440-1444.
10. Herrera VM, Didishvili T, Lopez LV, et al.: Hypertension exacerbates coronary artery disease in transgenic hyperlipidemic Dahl salt-sensitive hypertensive rats. Mol Med 2001, 7:831-844. The mechanisms by which modulation of blood pressure may affect coronary artery disease is difficult to study in patients. The transgenic model in this paper in many ways mimics the postmortem histopathology found in patients. This type of model has the potential to unravel the interaction between blood pressure and acute coronary syndromes.
11. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-153.
12. Mann JF, Gerstein HC, Pogue J, et al.: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001, 134:629-636. Much of the effect seen in the HOPE cohort was driven by high-risk patients such as those with diabetes and/or renal impairment.
13. Svensson P, de Faire U, Sleight P, et al.: Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 2001, 38:E28-E32.
14. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003. Landmark study demonstrating that for hypertensive patients with severe LVH, losartan- based therapy is superior to atenolol-based therapy with a significant reduction in stroke, LV mass, and new-onset diabetes.
15. Kramer C, Sunkomat J, Witte J, et al.: Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002, 90:770-776. A metabolite of losartan has anti-platelet activity. Could this help explain why the mechanism by losartan was superior to atenolol in the LIFE study?
16. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288:2981-2997. Confirms that thiazide diuretic is the best first-line treatment in a wide range of patients. However, with lower-target blood pressure a combination of antihypertensive medications will be required for most patients.
17. Keltai M, Johnson JA, Kowey PR, et al.: INVEST substudies: design and patient characteristics. Clin Cardiol 2001, 24:V9-11. Likely to help answer the question as to best combination antihypertensive medication in patients with coronary artery disease. May report 2003.
18. Hasebe N, Kido S, Ido A, et al.: Reverse J-curve relation between diastolic blood pressure and severity of coronary artery lesion in hypertensive patients with angina pectoris. Hypertens Res 2002, 25:381-387.
19. Kurpesa M, Trzos E, Drozdz J, et al.: Myocardial ischemia and autonomic activity in dippers and non-dippers with coronary artery disease: assessment of normotensive and hypertensive patients. Int J Cardiol 2002, 83:133-142.
20. Avanzini F, Ferrario G, Santoro L, et al.: Risks and benefits of early treatment of acute myocardial infarction with an angiotensin-converting enzyme inhibitor in patients with a history of arterial hypertension: analysis of the GISSI-3 database. Am Heart J 2002, 144:1018-1025. New data demonstrates the risk of early ACE-inhibitor treatment for AMI patients with a history of hypertension and systolic BP less than 120 mm Hg.
21. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001, 357:995-1001. Despite the evidence base, guidelines and resource, in practice there has been little demonstrable improvement in the diagnosis and treatment of patients with hypertension.
22. Amar J, Chamontin B, Ferrieres J, et al.: Hypertension control at hospital discharge after acute coronary event: influence on cardiovascular prognosis - the PREVENIR study. Heart 2002, 88:587-591.